Search
forLearn
5 / 31 resultslearn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn Follistatin
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
learn Exosomes
Microscopic delivery system that sends growth-promoting signals to hair follicles
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Research
5 / 1000+ results
research Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor
Finasteride effectively blocks enzyme causing male pattern baldness.
research Cloning, Expression, and Characterization of Rhesus Macaque Types 1 and 2 5alpha-Reductase: Evidence for Mechanism-Based Inhibition by Finasteride
Finasteride inhibits enzyme activity in rhesus macaques, suggesting they're useful for evaluating similar drugs.
research Chemical Mechanism of the Covalent Modification of 5-Alpha-Reductases by Finasteride as Probed by Secondary Tritium Isotope Effects
Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.
research Inhibition of Rat Alpha-Reductases by Finasteride: Evidence for Isozyme Differences in the Mechanism of Inhibition
Finasteride effectively blocks rat enzymes, but with varying methods and strength.
research Caffeic Acid N-[3,5-Bis(Trifluoromethyl)Phenyl] Amide as a Non-Steroidal Inhibitor for Steroid 5α-Reductase Type 1 Using a Human Keratinocyte Cell-Based Assay and Molecular Dynamics
Compound 4 is a promising treatment for hair loss with low toxicity.
Community Join
5 / 722 results
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community How much would a high dose dutasteride scalp dht inhibition be?
The conversation discusses the potential for high doses of dutasteride to completely inhibit scalp DHT and speculates whether this could cure baldness when combined with a topical antiandrogen. Specific dosages mentioned are 0.5 mg reducing scalp DHT by 55% and 2.5 mg by about 79%.
community [1.4 years] [Day 240 dutasteride][pics] hair loss gets worse, I am a complete non responder, DHT inhibition does not halt hair loss for me. Should I try minoxidil?
The user experienced worsening hair loss despite using finasteride and dutasteride. They are considering trying minoxidil but are unsure if it will help.
community A concise, easy-to-understand post on Androgenic Alopecia theory and its practical applications
The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.
community Update about Hair Follicle Glucose Metabolism: New Clinical Data Collection with Ex-President Of American Board Of Hair Restoration Surgery.
David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.